SEC v. Bruce Cameron Conway — U.S. Securities and Exchange Commission Litigation Release No. 26568, dated June 16, 2026.
The SEC charged Bruce Cameron Conway with insider trading. Conway allegedly used confidential information about a private biotech firm's merger plans to buy shares of the public company it was merging with, Cancer Genetics. He then sold his shares after the merger was announced, profiting from the price increase.
Imagine you hear a secret about a friend's company that it's going to be bought by a bigger company, which will make its stock price go up. If you buy that company's stock before the secret is public, and then sell it after the news is out, that's like insider trading. Bruce Conway was accused of doing this with a biotech company's stock, making over $60,000.
Disclaimer: all facts are drawn from the SEC's own filings; the claims described are allegations unless and until a court rules or the parties settle, and some cases end in dismissal.
SEC Settles Litigation with Texas Resident Charged with Insider Trading. On June 15, the Securities and Exchange Commission filed a consent and proposed final judgment as to defendant Bruce Cameron Conway, whom the SEC previously charged with insider trading. The SEC’s complaint, filed on August 7, 2025 in the U.S. District Court for the Northern District of Texas, alleged that in July 2020, after agreeing to confidentiality terms, Conway obtained material nonpublic information regarding a privately- held biotechnology firm in which Conway was invested and its plan to merge with Cancer Genetics. The complaint further alleged Conway purchased Cancer Genetics shares on the basis of that information in fifteen accounts belonging to him, his family members, and family-owned trusts. As alleged, on August 24, 2020, the merger was publicly announced, the price of Cancer Genetics stock rose by 215 percent from the previous day’s closing price, and Conway began selling his Cancer Genetics shares. Without admitting the allegations in the SEC’s complaint, Conway consented to the entry of a final judgment, subject to court approval, in which he agreed to be permanently enjoined from violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder; and to pay disgorgement of $60,201.95, prejudgment interest of $19,461.39, and a civil penalty of $160,936.22. The SEC’s litigation was conducted by John Dwyer and Jodanna Haskins, under the supervision of Gregory A. Kasper. The SEC’s investigation was conducted by John Dwyer and supervised by Kimberly Frederick and Nicholas Heinke, all of the SEC’s Denver Regional Office. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.
Named in this action: Bruce Cameron Conway.